Jiang T, Zeng Q, Wang J
Mol Cell Biochem. 2024; .
PMID: 39466483
DOI: 10.1007/s11010-024-05142-6.
Yuan F, Han X, Huang M, Su Y, Zhang Y, Hu M
Cell Mol Gastroenterol Hepatol. 2024; 19(2):101420.
PMID: 39414025
PMC: 11652890.
DOI: 10.1016/j.jcmgh.2024.101420.
Seetharaman S, Devany J, Kim H, van Bodegraven E, Chmiel T, Tzu-Pin S
bioRxiv. 2024; .
PMID: 38948838
PMC: 11212908.
DOI: 10.1101/2024.06.16.599227.
Zhang J, Zeng Q, She M
Clin Exp Med. 2023; 23(7):3113-3124.
PMID: 37103649
DOI: 10.1007/s10238-023-01076-3.
Gao X, Yang L
Oncol Lett. 2023; 25(5):186.
PMID: 37065787
PMC: 10091182.
DOI: 10.3892/ol.2023.13772.
QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway.
Anwaier G, Xie T, Pan C, Li A, Yan L, Wang D
Front Pharmacol. 2022; 13:918335.
PMID: 35910357
PMC: 9326396.
DOI: 10.3389/fphar.2022.918335.
The Roles of FHL3 in Cancer.
Huang Z, Yu C, Yu L, Shu H, Zhu X
Front Oncol. 2022; 12:887828.
PMID: 35686099
PMC: 9171237.
DOI: 10.3389/fonc.2022.887828.
High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells.
Li N, Xu L, Zhang J, Liu Y
Int J Exp Pathol. 2022; 103(3):90-101.
PMID: 35366027
PMC: 9107608.
DOI: 10.1111/iep.12436.
The titin N2B and N2A regions: biomechanical and metabolic signaling hubs in cross-striated muscles.
Van der Pijl R, Domenighetti A, Sheikh F, Ehler E, Ottenheijm C, Lange S
Biophys Rev. 2021; 13(5):653-677.
PMID: 34745373
PMC: 8553726.
DOI: 10.1007/s12551-021-00836-3.
Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.
Wei X, Zhang H
Cancer Biol Med. 2020; 17(2):270-281.
PMID: 32587768
PMC: 7309467.
DOI: 10.20892/j.issn.2095-3941.2019.0420.
Aberrant Protein Turn-Over Associated With Myofibrillar Disorganization in FHL1 Knockout Mice.
Ding J, Cong Y, Liu B, Miao J, Wang L
Front Genet. 2018; 9:273.
PMID: 30083183
PMC: 6065255.
DOI: 10.3389/fgene.2018.00273.
Differentially Methylated Genes in Saliva are linked to Childhood Stress.
Papale L, Seltzer L, Madrid A, Pollak S, Alisch R
Sci Rep. 2018; 8(1):10785.
PMID: 30018309
PMC: 6050255.
DOI: 10.1038/s41598-018-29107-0.
Four and a half LIM domain protein signaling and cardiomyopathy.
Liang Y, Bradford W, Zhang J, Sheikh F
Biophys Rev. 2018; 10(4):1073-1085.
PMID: 29926425
PMC: 6082310.
DOI: 10.1007/s12551-018-0434-3.
The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling.
Dierck F, Kuhn C, Rohr C, Hille S, Braune J, Sossalla S
J Biol Chem. 2017; 292(37):15180-15191.
PMID: 28717008
PMC: 5602380.
DOI: 10.1074/jbc.M117.786764.
Overview of the Muscle Cytoskeleton.
Henderson C, Gomez C, Novak S, Mi-Mi L, Gregorio C
Compr Physiol. 2017; 7(3):891-944.
PMID: 28640448
PMC: 5890934.
DOI: 10.1002/cphy.c160033.
LIM-Only Protein FHL2 Is a Negative Regulator of Transforming Growth Factor β1 Expression.
Dahan J, Levillayer F, Xia T, Nouet Y, Werts C, Fanton dAndon M
Mol Cell Biol. 2017; 37(10).
PMID: 28223370
PMC: 5477553.
DOI: 10.1128/MCB.00636-16.
FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer.
Wu M, Tang W, Zhan X, Li Y, Peng Y, Huang X
Oncogenesis. 2016; 5(11):e271.
PMID: 27892920
PMC: 5141290.
DOI: 10.1038/oncsis.2016.68.
The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription.
Hua G, He C, Lv X, Fan L, Remmenga S, Rodabaugh K
Cell Death Dis. 2016; 7:e2297.
PMID: 27415427
PMC: 4973349.
DOI: 10.1038/cddis.2016.207.
Mammalian Actin-binding Protein-1/Hip-55 Interacts with FHL2 and Negatively Regulates Cell Invasion.
Boateng L, Bennin D, de Oliveira S, Huttenlocher A
J Biol Chem. 2016; 291(27):13987-13998.
PMID: 27129278
PMC: 4933159.
DOI: 10.1074/jbc.M116.725739.
Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.
Jin H, Lee K, Kim Y, Oh H, Maeng Y, Kim T
Oncogene. 2016; 35(39):5106-18.
PMID: 26973248
PMC: 5399145.
DOI: 10.1038/onc.2016.54.